Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D00WCX
|
||||
Former ID |
DAP001182
|
||||
Drug Name |
Bezafibrate
|
||||
Synonyms |
Azufibrat; Befibrat; Befizal; BezaLande; BezaPuren; Bezabeta; Bezacur; Bezafibrat; Bezafibrato; Bezafibratum; Bezafisal;Bezalip; Bezamerck; Bezatol; Cedur; Difaterol; Durabezur; Eulitop; Lipox; Reducterol; Sklerofibrat; Solibay; Azupharma Brand of Bezafibrate; Bayer Brand of Bezafibrate; Berlin Chemie Brand of Bezafibrate; Betapharm Brand of Bezafibrate; Beza Lande; Beza Puren; Bezafibrat PB; Bezafibrate Azupharma Brand; Bezafibrate Bayer Brand; Bezafibrate Betapharm Brand; Bezafibrate Cryopharma Brand; Bezafibrate Elfar Brand; Bezafibrate Hennig Brand; Bezafibrate Hexal Brand; Bezafibrate Isis Brand; Bezafibrate Lakeside Brand; Bezafibrate Merckle Brand; Bezafibrate Roche Brand; Bezafibrate Synthelabo Brand; Bezafibrate TAD Brand; Bezafibrate Teva Brand; Bezafibrato [Spanish]; Bezalip Retard; Bezatol SR; Boehringer Mannheim Brand of Bezafibrate; Cryopharma Brand of Bezafibrate; Elfar Brand of Bezafibrate;Hennig Brand of Bezafibrate; Hexal Brand of Bezafibrate; Isis Brand of Bezafibrate; Lakeside Brand of Bezafibrate; Merckle Brand of Bezafibrate; Regadrin B; Roche Brand of Bezafibrate; Synthelabo Brand of Bezafibrate; TAD Brand of Bezafibrate; Teva Brand of Bezafibrate; BM 15075; LO 44; BF-759; BM 15.075; BM-15075; BM15.075; Berlin-Chemie Brand of Bezafibrate; Beza-Lande; Beza-Puren; Bezafibrate Berlin-Chemie Brand; Bezafibrato [INN-Spanish]; Bezafibratum [INN-Latin]; Bezalip (TN); Bezatol SR (TN); PB, Bezafibrat; BM-15.075; Bezafibrate (JP15/USAN/INN); Bezafibrate [USAN:BAN:INN:JAN]; A-[4-(4-chlorobenzoylaminoethyl)phenoxy]isobutyric acid; 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid; 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; 2-[4-(2-[4-Chlorobenzamido]ethyl)-phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Antilipemic Agents
|
||||
Structure |
Download2D MOL |
||||
Formula |
C19H20ClNO4
|
||||
InChI |
InChI=1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)
|
||||
InChIKey |
IIBYAHWJQTYFKB-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 41859-67-0
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
855877, 3221863, 4720908, 7848429, 7978783, 8149814, 8175852, 10321679, 11112764, 11121379, 11121859, 11335267, 11360506, 11362448, 11364337, 11365010, 11366899, 11367572, 11369461, 11370167, 11370168, 11372718, 11373173, 11373808, 11375734, 11377623, 11461478, 11466406, 11467526, 11484560, 11486192, 11488738, 11491315, 11492140, 11495257, 12015374, 14926008, 24891983, 26612282, 26680411, 26747025, 26747026, 26751545, 26751546, 26751547, 29214784, 34704995, 46509188, 47217032, 47291353
|
||||
ChEBI ID |
ChEBI:47612
|
||||
SuperDrug ATC ID |
C10AB02
|
||||
SuperDrug CAS ID |
cas=041859670
|
||||
Target and Pathway | |||||
Target(s) | Peroxisome proliferator activated receptor alpha | Target Info | Agonist | [537006] | |
Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | ||||
Reactome | RORA activates gene expression | ||||
BMAL1:CLOCK,NPAS2 activates circadian gene expression | |||||
PPARA activates gene expression | |||||
YAP1- and WWTR1 (TAZ)-stimulated gene expression | |||||
Transcriptional activation of mitochondrial biogenesis | |||||
Activation of gene expression by SREBF (SREBP) | |||||
Transcriptional regulation of white adipocyte differentiation | |||||
Nuclear Receptor transcription pathway | |||||
Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||||
Circadian Clock | |||||
WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
Nuclear Receptors Meta-Pathway | |||||
Estrogen Receptor Pathway | |||||
PPAR Alpha Pathway | |||||
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||||
Transcriptional Regulation of White Adipocyte Differentiation | |||||
YAP1- and WWTR1 (TAZ)-stimulated gene expression | |||||
Activation of Gene Expression by SREBP (SREBF) | |||||
Adipogenesis | |||||
SREBF and miR33 in cholesterol and lipid homeostasis | |||||
Circadian Clock | |||||
Nuclear Receptors | |||||
References | |||||
Ref 539733 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2668). | ||||
Ref 550550 | Antidiabetic action of bezafibrate in a large observational database. Diabetes Care. 2009 Apr;32(4):547-51. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.